Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling

The purpose of the investigation was to test the use of alendronate in the therapy of children affected by chronic rheumatic diseases and symptomatic drug-induced osteoporosis. Two courses of alendronate were intravenously administered to four girls with vertebral fractures that were glucocorticoid...

Full description

Saved in:
Bibliographic Details
Published in:Calcified tissue international 1996-03, Vol.58 (3), p.166-169
Main Authors: Falcini, F, Trapani, S, Ermini, M, Brandi, M L
Format: Article
Language:English
Subjects:
Adolescent
Alendronate - administration & dosage
Bone Density
Bone Remodeling - drug effects
Child
Female
Glucocorticoids - antagonists & inhibitors
Humans
Injections, Intravenous
Osteoporosis - diagnostic imaging
Osteoporosis - pathology
Radiography
Rheumatic Diseases - drug therapy
Spine - diagnostic imaging
Spine - pathology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of the investigation was to test the use of alendronate in the therapy of children affected by chronic rheumatic diseases and symptomatic drug-induced osteoporosis. Two courses of alendronate were intravenously administered to four girls with vertebral fractures that were glucocorticoid induced. Improvement of back pain and bone mineral density increase evaluated by DXA and conventional spine X-rays were observed. Our study supports the ABD-induced improvement of the negative effects of long-term therapy on bone mineral density in children with chronic rheumatic diseases.
ISSN:0171-967X
1432-0827
DOI:10.1007/s002239900028